(4-氨基-2-甲基苯基)甲醇 | 63405-88-9

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氨基-2-甲基苯基)甲醇
• 中文别名: 2-甲基-4-氨基苯甲醇
• 英文名称: 4-amino-2-methyl-benzyl alcohol
• 英文别名: 4-Amino-2-methylbenzylalkohol；(4-Amino-2-methylphenyl)methanol
• CAS: 63405-88-9
• 化学式: C₈H₁₁NO
• mdl: MFCD11110504
• 分子量: 137.181
• InChiKey: DZLYWPKCBRSMIB-UHFFFAOYSA-N

物化性质

• 熔点：
  80-81 °C
• 沸点：
  298.4±25.0 °C(Predicted)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  (4-氨基-2-甲基苯基)甲醇 在 1,3-二溴-5,5-二甲基海因 、 三乙胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 9.5h， 生成 (4-乙酰氨基-5-氰基-2-甲基苯基)乙酸甲酯
  参考文献：
  名称：

  Chemical Development of ZD9331:  Synthesis of a Bromomethylquinazolinone Avoiding a Nonselective Radical Bromination

  摘要：

  An efficient regiospecific synthesis of ZD9331 Pivaloyloxymethyl (POM) Bromide ( 4) has been accomplished via ZD9331 Quinacetate HCl ( 15) avoiding a nonselective bromination. The original route used a radical bromination on a substrate with three methyl groups, which generated a range of bromomethyl derived compounds that carried through to the final active pharmaceutical ingredient (API). A strategy, based on the Zinin reaction, was developed to synthesize the required bromomethyl compound in a regioselective manner. This approach was successfully scaled to manufacture a tonne of material.

  DOI：

  10.1021/op060049a
• 作为产物：
  描述：

  4-硝基邻二甲苯 在 甲醇 、 sodium tetrahydroborate 作用下， 生成 (4-氨基-2-甲基苯基)甲醇
  参考文献：
  名称：

  Chemical Development of ZD9331:  Synthesis of a Bromomethylquinazolinone Avoiding a Nonselective Radical Bromination

  摘要：

  An efficient regiospecific synthesis of ZD9331 Pivaloyloxymethyl (POM) Bromide ( 4) has been accomplished via ZD9331 Quinacetate HCl ( 15) avoiding a nonselective bromination. The original route used a radical bromination on a substrate with three methyl groups, which generated a range of bromomethyl derived compounds that carried through to the final active pharmaceutical ingredient (API). A strategy, based on the Zinin reaction, was developed to synthesize the required bromomethyl compound in a regioselective manner. This approach was successfully scaled to manufacture a tonne of material.

  DOI：

  10.1021/op060049a

文献信息

• 2-AMINOQUINAZOLINE DERIVATIVES
  申请人：Kishikawa Kuniyuki

  公开号：US20090137583A1

  公开（公告）日：2009-05-28

  The present invention provides 2-aminoquinazoline derivatives represented by formula (I): wherein R 1 and R 2 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X represents a bond or CR 7a R 7b wherein R 7a and R 7b may be the same or different and each represents a hydrogen atom, and the like; when X is a bond, R 3 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; when X is CR 7a R 7b wherein R 7a and R 7b have the same meanings as defined above, respectively, R 3 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, and the like; R 4 represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, and the like; and R 5 represents a hydrogen atom, substituted or unsubstituted aryl, and the like, or a pharmaceutically acceptable salt thereof.

  本发明提供了由式(I)表示的2-氨基喹唑啉衍生物：其中R1和R2可以相同或不同，每个代表氢原子，取代或未取代的低烷基等；X表示键或CR7aR7b，其中R7a和R7b可以相同或不同，每个代表氢原子等；当X为键时，R3表示取代或未取代的芳基或取代或未取代的芳香杂环基；当X为CR7aR7b时，其中R7a和R7b的含义分别如上所定义，R3表示取代或未取代的低烷氧基，取代或未取代的芳基等；R4表示氢原子，羟基，取代或未取代的低烷氧基等；而R5表示氢原子，取代或未取代的芳基等，或其药学上可接受的盐。
• Aryl substituted azabenzimidazoles and their use in the treatment of HIV and AIDS related diseases
  申请人：Pfizer Products Inc.

  公开号：EP1125936A2

  公开（公告）日：2001-08-22

  This invention relates to novel aryl substituted azabenzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof wherein n is an integer from 1 to 4 X is CH or N; R1 is H, (C1-C6)alkyl or (C1-C6) alkoxy; R2 is H, (C1-C6)alkyl or (C1-C6) alkoxy; each R3 is independently selected from H, (C1-C6)alkyl (C1-C6) alkyloxy, (C1-C6) alkylthio, halo, nitro, cyano, ethynyl, hydroxyand trifluoromethyl; R4 is H, (C1-C6)alkyl or (C1-C6) alkoxy; R5 is H, (C1-C6)alkyl or (C1-C6)alkyloxy, trifluoromethyl; and W is N or C; Y is N (R4), N, S or O Z is R4, NR4H, O, or OH; Provided that when Y = NR4, W = C, Z = O, there is a single bond between YW and a double bond between WZ; and when Y = O or S, W = C, Z = O, there is a single bond between YW and a double bond between WZ; and when Y = N, W = N, there is a double bond between YW and Z does not exist. when Y = N, W = C, Z = R4 or NHR4, there is a double bond between YW and a single bond between WZ; The methods of preparing these compounds and their use in the treatment of HIV, AIDS, and AIDS related diseases and in slowing the progression of HIV infection into AIDS is also disclosed.

  本发明涉及新型芳基取代的式(I)氮杂苯并咪唑及其药学上可接受的盐。 或其药学上可接受的盐，其中 n 是 1 至 4 的整数 X 是 CH 或 N R1 是 H、(C1-C6)烷基或 (C1-C6) 烷氧基； R2 是 H、(C1-C6)烷基或 (C1-C6) 烷氧基； 每个 R3 都独立选自 H、(C1-C6)烷基、(C1-C6)烷氧基、(C1-C6)烷硫基、卤代、硝基、氰基、乙炔基、羟基和三氟甲基； R4 是 H、(C1-C6)烷基或 (C1-C6) 烷氧基； R5 是 H、(C1-C6)烷基或(C1-C6)烷氧基、三氟甲基；以及 W 是 N 或 C； Y 是 N (R4)、N、S 或 O Z 是 R4、NR4H、O 或 OH； 但当 Y = NR4、W = C、Z = O 时，YW 之间为单键，WZ 之间为双键；以及 当 Y = O 或 S，W = C，Z = O 时，YW 之间为单键，WZ 之间为双键；以及 当 Y = N，W = N 时，YW 之间存在双键，Z 不存在。 当Y＝N，W＝C，Z＝R4或NHR4时，YW之间存在双键，WZ之间存在单键；还公开了制备这些化合物的方法及其在治疗HIV、艾滋病和艾滋病相关疾病以及延缓HIV感染发展为艾滋病方面的用途。
• [EN] CYTOTOXIC AGENT AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] AGENT CYTOTOXIQUE ET CONJUGUÉ DE CELUI-CI, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 细胞毒性剂及其偶联物、其制备方法及用途
  申请人：SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

  公开号：WO2019154120A1

  公开（公告）日：2019-08-15

  一种新型细胞毒性剂（其为喜树碱衍生物），其与靶向物的偶联物、所述细胞毒性剂和偶联物的制备方法，以及所述偶联物在预防和/或治疗与细胞活性异常相关的增殖性疾病（包括但不限于癌症疾病）中的用途。
• Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA–PABA–MAC and 5-ASA–PABA–Diamine for the Treatment of Ulcerative Colitis
  作者：Jiaxing Zhao、Bing Zhang、Qing Mao、Kunqi Ping、Peng Zhang、Fengwei Lin、Dan Liu、Yao Feng、Ming Sun、Yan Zhang、Qiu Hua Li、Tingjian Zhang、Yanhua Mou、Shaojie Wang

  DOI：10.1021/acs.jmedchem.1c02166

  日期：2022.3.24
• Nayar, Mazhuvadyil R. Gopinathan; Francis, Joseph D., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1983, vol. <B> 22, # 8, p. 776 - 780
  作者：Nayar, Mazhuvadyil R. Gopinathan、Francis, Joseph D.

  DOI：——

  日期：——